Dr Aldo Trylesinski is Consulting CMO for Metadeq, while continuing to serve full-time as Executive Medical Director at AdvanzaPharma, with a focus on Hepatology. He is responsible for the strategy and implementation of pre-launch medical activities, including development and support of medical regulatory and R&D activities for biomarkers and new therapies for patients with MASH, liver fibrosis & cirrhosis. Specific job duties include: clinical trial implementation and execution, running educational programmes, Advisory Boards, KOL and scientific society collaboration, and delivering scientific publications. He previously worked in Novartis headquarters as Sr Global Medical Director in a range of different disease areas including Hepatitis, Liver Transplant, Cell & Gene Therapies for 7 years. Prior to that he worked in medical leadership roles at Gilead and Roche. He completed his training in Internal Medicine and Hepato-Gastroenterology in France. He worked as Affiliate Physician in the Immunology Clinical Department at the Academic European Georges Pompidou Hospital in Paris until 2009, as well as in other several other hospitals. He holds a Hepato-Gastroenterology diploma, a French board qualification in internal medicine, a post-doc in imaging techniques, a post-doc in nutrition and a post-doc in AIDS and retroviruses. He has contributed to more than 80 public & pharmaceutical company clinical trials. He more than 90 publications in the fields of liver, immunology, treatment of viral hepatitis & liver transplantation. He joined EASL in 1987. He is interested in reimagining medicine, transforming science and improving health outcomes for patients.